Large American pharmaceutical companies are showing a distinct trend never seen before: they are increasingly looking for ...

Pharmacy spend will rise 3.8%, driven in part by increased demand for specialty medications. AbbVie’s autoimmune disease drug Humira will continue to be the most popular drug by total spend ...

Just as Andrew Witty of UnitedHealth Group did in a call with investors last month, CVS Health’s CEO David Joyner defended ...

AbbVie, Danaher, Vertex Pharmaceuticals ... and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional ...

and that shift is reflected in the list of the top 15 drugs by total spend for Vizient pharmacy program participants. Humira®, manufactured by AbbVie, is again at the top of the list and ...

and that shift is reflected in the list of the top 15 drugs by total spend for Vizient pharmacy program participants. Humira®, manufactured by AbbVie, is again at the top of the list and semaglutide ...

Ten months after Pfizer scored approval in Europe for Emblaveo (aztreonam and avibactam) to treat complicated intra-abdominal infections (cIAIs), AbbVie has done the same in the U.S., winning an ...

AbbVie (NYSE: ABBV) closed out a pivotal 2024 with an excellent fourth-quarter earnings report. For the period ended Dec. 31, the biopharmaceuticals giant delivered 6% sales growth and $2.12 in ...

UCB’s Bimzelx is firmly on physicians’ radars, with Spherix Global Insights finding that awareness of the drug was tracking ahead of AbbVie’s Rinvoq and Skyrizi three months into its ...

The FDA has approved AbbVie’s Emblaveo (aztreonam and avibactam) for adults with complicated intra-abdominal infections (cIAI) who have limited or no alternative treatment options. The regulatory ...